New drug combo shows promise for tough bladder cancer
NCT ID NCT03258593
First seen Jan 06, 2026 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This early-phase trial tested two drugs—durvalumab and vicineum—in 15 people with high-grade non-muscle-invasive bladder cancer that had not responded to standard BCG treatment. The goal was to see if the combination is safe and can help the immune system fight the cancer. Participants received the drugs for up to 2 years, with regular check-ups and tumor samples.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for URINARY BLADDER NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (Imfinzi) and vicineum (oportuzumab monatox)
What this could lead to
If it works, this combination could offer a new treatment option for people with early-stage bladder cancer that hasn't responded to standard therapy.
What could go wrong
This is a very early, small phase 1 trial with only 15 participants, so results may not apply to everyone. The main goal is safety, not proof of effectiveness, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.